These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 15184349

  • 1. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
    Schneider MP, Klingbeil AU, Delles C, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE.
    Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
    [Abstract] [Full Text] [Related]

  • 2. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Müller-Brunotte R, Kahan T, López B, Edner M, González A, Díez J, Malmqvist K.
    J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
    [Abstract] [Full Text] [Related]

  • 3. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R, Kahan T, Malmqvist K, Ring M, Edner M.
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [Abstract] [Full Text] [Related]

  • 4. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L.
    J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
    [Abstract] [Full Text] [Related]

  • 5. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations.
    Circulation; 2003 Aug 12; 108(6):684-90. PubMed ID: 12885747
    [Abstract] [Full Text] [Related]

  • 6. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
    Malmqvist K, Kahan T, Edner M, Bergfeldt L.
    Am J Cardiol; 2002 Nov 15; 90(10):1107-12. PubMed ID: 12423712
    [Abstract] [Full Text] [Related]

  • 7. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
    Kurland L, Hallberg P, Melhus H, Liljedahl U, Hashemi N, Syvänen AC, Lind L, Kahan T.
    Am J Hypertens; 2008 Jul 15; 21(7):836-9. PubMed ID: 18464745
    [Abstract] [Full Text] [Related]

  • 8. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    JAMA; 2004 Nov 17; 292(19):2343-9. PubMed ID: 15547161
    [Abstract] [Full Text] [Related]

  • 9. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
    Mörtsell D, Malmqvist K, Held C, Kahan T.
    J Intern Med; 2007 May 17; 261(5):472-9. PubMed ID: 17444886
    [Abstract] [Full Text] [Related]

  • 10. Beta blockers & left ventricular hypertrophy regression.
    George T, Ajit MS, Abraham G.
    Indian Heart J; 2010 May 17; 62(2):139-42. PubMed ID: 21180305
    [Abstract] [Full Text] [Related]

  • 11. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L.
    Am J Hypertens; 2002 May 17; 15(5):389-93. PubMed ID: 12022239
    [Abstract] [Full Text] [Related]

  • 12. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Hallberg P, Lind L, Michaëlsson K, Karlsson J, Kurland L, Kahan T, Malmqvist K, Ohman KP, Nyström F, Melhus H.
    J Hypertens; 2003 Mar 17; 21(3):621-4. PubMed ID: 12640257
    [Abstract] [Full Text] [Related]

  • 13. Regression of left ventricular hypertrophy in human hypertension with irbesartan.
    Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, Müller-Brunotte R, Nyström F, Ohman KP, Osbakken MD, Ostergern J.
    J Hypertens; 2001 Jun 17; 19(6):1167-76. PubMed ID: 11403367
    [Abstract] [Full Text] [Related]

  • 14. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T.
    J Hypertens Suppl; 1998 Sep 17; 16(7):S23-9. PubMed ID: 9855028
    [Abstract] [Full Text] [Related]

  • 15. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B.
    Hypertension; 2000 Nov 17; 36(5):766-73. PubMed ID: 11082141
    [Abstract] [Full Text] [Related]

  • 16. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Am J Hypertens; 1997 Jul 17; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [Abstract] [Full Text] [Related]

  • 17. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
    Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B.
    JAMA; 2006 Sep 13; 296(10):1242-8. PubMed ID: 16968848
    [Abstract] [Full Text] [Related]

  • 18. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Malmqvist K, Ohman KP, Lind L, Nyström F, Kahan T.
    J Cardiovasc Pharmacol; 2003 Dec 13; 42(6):719-26. PubMed ID: 14639093
    [Abstract] [Full Text] [Related]

  • 19. Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study.
    Malmqvist K, Kahan T, Edner M, Bergfeldt L.
    J Hum Hypertens; 2007 Dec 13; 21(12):956-65. PubMed ID: 17637792
    [Abstract] [Full Text] [Related]

  • 20. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study.
    Nyström F, Malmqvist K, Ohman KP, Kahan T.
    J Hypertens; 2002 Aug 13; 20(8):1527-33. PubMed ID: 12172314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.